Navigation Links
CRESTOR® Patent Upheld By US Court

WILMINGTON, Del., June 29 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that Judge Joseph Farnan, Jr., US District Court, District of Delaware, has found that the substance patent protecting CRESTOR (RE37,314 – the '314 patent) is valid and enforceable. In its ruling, the court found that no inequitable conduct was committed by any Shionogi employee. The court also held the '314 patent to be non-obvious and properly reissued.

(Logo: )

Judge Farnan's subsequent entry of judgment will preclude the FDA from issuing final approvals for the defendants' Abbreviated New Drug Applications (ANDAs) prior to the expiration of the '314 patent in 2016.  

"We are pleased with the court's decision upholding the validity and enforceability of the '314 substance patent," said David Brennan, Chief Executive Officer, AstraZeneca. "The court's decision reaffirms the strength of the intellectual property protecting CRESTOR.''

Judge Farnan also held that Apotex USA was liable as a submitter and is therefore bound to the court's decision.

About the Trial

Beginning in 2007, nine generic drug manufacturers filed ANDAs along with Paragraph IV certifications of non-infringement, invalidity, or unenforceability with respect to the CRESTOR patents. AstraZeneca and Shionogi (the owner of the '314 patent) filed patent infringement suits against eight manufacturers (various parent or subsidiary entities of Apotex, Aurobindo, Cobalt, Mylan, Par, Sandoz, Sun and Teva) who had challenged the '314 substance patent. The '314 patent, which expires in 2016, covers rosuvastatin calcium, the active ingredient in CRESTOR. These suits were consolidated by order of the Judicial Panel on Multidistrict Litigation and tried in the US District Court, District of Delaware. Trial commenced on February 22, 2010 before Judge Farnan and ended on March 3, 2010.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion dollar healthcare business.

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit:

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Announces Issuance of Patent for Alzheimers Disease Diagnosis
2. Bayer Sues Teva and Barr for False Advertising and Patent Infringement in Connection with Tevas Generic Oral Contraceptive Gianvi™
3. Amedica® Receives Patent for Hip Implant Using Monoblock Ceramic Technology
4. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
5. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
6. Biocept, Inc. Announces Issuance of Patent for its Microfluidic Technology
7. European Patent Office Upholds Molecular Devices Planar Patch Clamp Patent
8. Patent Awarded to the Design of TechniScans Unique 3-D Breast Imaging System
9. Solta Medical and Alma Lasers Resolve Patent Lawsuits
10. Pars Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R)
11. DUSA Pharmaceuticals Reports Notice of Allowance for Key PDT Device Patent
Post Your Comments:
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... Netherlands has found that immunotherapy can be ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... ... , ... Dr. Thomas Dunlap and Dr. Patrick Coleman , ... Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted ... similar ways and require time-critical intervention to avoid large area heart damage and progressive ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
Breaking Medicine News(10 mins):